Literature DB >> 29280829

A Case Series on Patients on Tofacitinib in Combination With a Biologic.

Nashla S Barroso1, Elizabeth Z Miller, Daniel E Furst.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29280829     DOI： 10.1097/RHU.0000000000000663

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN： 1076-1608            Impact factor:   3.517


× No keyword cloud information.
  4 in total

Review 1.  Janus kinases to jakinibs: from basic insights to clinical practice.

Authors:  Massimo Gadina; Mimi T Le; Daniella M Schwartz; Olli Silvennoinen; Shingo Nakayamada; Kunihiro Yamaoka; John J O'Shea
Journal:  Rheumatology (Oxford)       Date:  2019-02-01       Impact factor: 7.580

2.  JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Authors:  Daniella M Schwartz; Yuka Kanno; Alejandro Villarino; Michael Ward; Massimo Gadina; John J O'Shea
Journal:  Nat Rev Drug Discov       Date:  2017-12-28       Impact factor: 84.694

Review 3.  JAK inhibition as a new treatment strategy for patients with COVID-19.

Authors:  Jin Huang; Chi Zhou; Jinniu Deng; Jianfeng Zhou
Journal:  Biochem Pharmacol       Date:  2022-07-03       Impact factor: 6.100

4.  New era of treatment with biologics in rheumatology - is it time to shift paradigms in treatment with biologics?

Authors:  Anna Felis-Giemza
Journal:  Reumatologia       Date:  2019-10-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.